Holen Sie sich die Stockscreener-App
140.09
1.87%
2.57
Schlusskurs vom Vortag:
$137.52
Offen:
$137.52
24-Stunden-Volumen:
977.23K
Relative Volume:
1.12
Marktkapitalisierung:
$13.89B
Einnahmen:
$2.41B
Nettoeinkommen (Verlust:
$305.80M
KGV:
47.49
EPS:
2.95
Netto-Cashflow:
$492.20M
1W Leistung:
+2.53%
1M Leistung:
-1.85%
6M Leistung:
+38.18%
1J Leistung:
+18.26%
1-Tages-Spanne:
$137.02
$140.47
1-Wochen-Bereich:
$135.63
$140.73
52-Wochen-Spanne:
$84.23
$154.61
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
140.09 | 13.64B | 2.41B | 305.80M | 492.20M | 2.95 |
|
ZTS
Zoetis Inc
|
144.06 | 63.49B | 9.39B | 2.62B | 2.22B | 5.8121 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.04 | 43.84B | 29.96B | 957.25M | 4.77B | 0.2956 |
|
HLN
Haleon Plc Adr
|
9.48 | 40.97B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
19.31 | 22.52B | 16.70B | -157.13M | 1.19B | -0.1446 |
|
UTHR
United Therapeutics Corp
|
433.34 | 19.57B | 3.08B | 1.24B | 1.07B | 25.61 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-10 | Eingeleitet | Goldman | Buy |
| 2025-04-15 | Hochstufung | Needham | Hold → Buy |
| 2025-04-14 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Hold |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Why Neurocrine Biosciences Inc. stock could benefit from AI revolutionGold Moves & Reliable Intraday Trade Plans - Trung tâm Dự báo KTTV quốc gia
Neurocrine Biosciences: Buy Rated As Q3 2025 Earnings Catalyst Approaches (NASDAQ:NBIX) - Seeking Alpha
Can Neurocrine Biosciences Inc. stock maintain growth trajectoryJuly 2025 Pullbacks & Risk Managed Investment Entry Signals - Trung tâm Dự báo KTTV quốc gia
Neurocrine’s INGREZZA shows sustained efficacy at 40 mg dose By Investing.com - Investing.com Canada
Can Neurocrine Biosciences Inc. stock hit analyst price targetsMarket Risk Analysis & Fast Exit and Entry Trade Guides - Trung tâm Dự báo KTTV quốc gia
How risky is Neurocrine Biosciences Inc. stock nowTrade Volume Summary & Short-Term High Return Ideas - newser.com
Neurocrine Biosciences Announces Positive Data From Post-Hoc Analysis Of Tardive Dyskinesia Study - Nasdaq
Neurocrine’s INGREZZA shows sustained efficacy at 40 mg dose - Investing.com
Neurocrine shares data on INGREZZA 40 mg treatment for tardive dyskinesia - StreetInsider
Neurocrine Biosciences Presents New KINECT® 4 Post-Hoc Analysis Demonstrating Rapid and Sustained Therapeutic Efficacy of INGREZZA® (valbenazine) 40 mg Capsules - PR Newswire
What moving averages say about Neurocrine Biosciences Inc.July 2025 Analyst Calls & Weekly Stock Breakout Alerts - newser.com
Neurocrine Biosciences patents new VMAT2 inhibitors - BioWorld MedTech
Should Neurocrine Biosciences' (NBIX) KINECT-HD2 Data and New Leadership Prompt Investor Action? - simplywall.st
Neurocrine Biosciences Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
Does the Recent Rare Earths News Move the Needle for Neurocrine Biosciences Valuation? - simplywall.st
Why Neurocrine Biosciences Inc. stock is trending among retail traders2025 Market WrapUp & Accurate Trade Setup Notifications - newser.com
United States Huntington's Disease Market is expected to reach - openPR.com
Is Neurocrine Biosciences Inc a good long term investmentChart Pattern Recognition & Ride the Trends That Billionaires Follow - earlytimes.in
Neurocrine Biosciences (NBIX): Evaluating Valuation Following Recent Clinical Milestones and Leadership Appointment - simplywall.st
Using data models to predict Neurocrine Biosciences Inc. stock movementOil Prices & Weekly Top Gainers Trade List - newser.com
Market reaction to Neurocrine Biosciences Inc.’s recent newsEarnings Performance Report & Daily Oversold Stock Bounce Ideas - newser.com
UBS Group Forecasts Strong Price Appreciation for Neurocrine Biosciences (NASDAQ:NBIX) Stock - MarketBeat
Using economic indicators to assess Neurocrine Biosciences Inc. potential2025 Support & Resistance & Daily Profit Focused Stock Screening - newser.com
Neurocrine Biosciences' (NBIX) "Hold (C+)" Rating Reaffirmed at Weiss Ratings - MarketBeat
How to forecast Neurocrine Biosciences Inc. trends using time seriesJuly 2025 Final Week & Verified Momentum Stock Watchlist - newser.com
Full technical analysis of Neurocrine Biosciences Inc. stockJuly 2025 Recap & Fast Gain Swing Alerts - newser.com
Neurocrine Bio. stock price target raised to $195 from $188 at UBS - Investing.com Nigeria
UBS Raises Neurocrine Biosciences Price Target to $195 From $188, Maintains Buy Rating - MarketScreener
Why Neurocrine Biosciences Inc. (NB3) stock fits value portfoliosQuarterly Trade Summary & Weekly Consistent Profit Watchlists - newser.com
Neurocrine Biosciences publishes positive data from movement disorder study - MSN
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2025 Financial Results - cnhinews.com
RBC Lifts Price Target on Neurocrine Biosciences to $156 From $149, Keeps Outperform Rating - MarketScreener
Neurocrine Biosciences Appoints Mike Sibley as Senior Vice President, General Manager of Neuropsychiatry Franchise - Eastern Progress
Truist Financial Corp Raises Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Q3 2025 Results: Neurocrine Biosciences to Host Oct. 28 Webcast & Call at 1:30 p.m. PT; Replay 1 Month - Stock Titan
How New Three-Year INGREZZA Data at Neurocrine Biosciences (NBIX) Has Changed Its Investment Story - simplywall.st
A Fresh Look at Neurocrine Biosciences (NBIX) Valuation After Latest INGREZZA Clinical Study Results - Yahoo Finance
Neurocrine Biosciences, Inc. $NBIX Stock Holdings Boosted by QRG Capital Management Inc. - MarketBeat
Earnings call transcript: Neurocrine Q2 2025 shows strong sales growth By Investing.com - Investing.com Australia
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise By Investing.com - Investing.com Nigeria
Neurocrine reports sustained benefits of INGREZZA for Huntington’s chorea By Investing.com - Investing.com Nigeria
Neurocrine Biosciences names Mike Sibley to lead neuropsychiatry franchise - Investing.com
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
15.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):